Menu Search
Equities

Iovance Biotherapeutics Inc

2LB:MUN

Iovance Biotherapeutics Inc

Actions
  • Price (EUR)11.21
  • Today's Change0.345 / 3.18%
  • Shares traded63.00
  • 1 Year change+127.70%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 07:04 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.

  • Revenue in USD (TTM)1.19m
  • Net income in USD-444.04m
  • Incorporated2017
  • Employees557.00
  • Location
    Iovance Biotherapeutics Inc825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS 94070United StatesUSA
  • Phone+1 (650) 260-7120
  • Fax+1 (302) 697-4597
  • Websitehttps://www.iovance.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.